| Ytd | 80.35% | |
| 1y | -40.73% |
| Open | 23.11 | Prev Close | 23.37 | Low | 22.80 | High | 23.79 | Mkt Cap | 1.28B |
| Vol | 0.00 | Avg Vol | 1.18M | EPS | -3.16 | P/E | -7.47 | Forward P/E | -6.33 |
| Beta | 1.72 | Short Ratio | 3.86 | Inst. Own | 83.35% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 17.69 | 200-d Avg | 15.32 | 1yr Est | 37.88 |
VOR News
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp
Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitac
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp
Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for
First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in Chi
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on p
BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnolo
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology compa
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks w
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis p
The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empiric
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology compa
The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor
Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and up
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) was the target of a large growth in short interes
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 484,104
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 135,201
Vor Biopharma Inc. has pivoted to immunology, raising over $500m in 2025 to advance telitacicept for
Shares of Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) have earned a consensus rating of "Mode
U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend.
On Tuesday, 647 companies set new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
During Tuesday's trading, 188 companies set new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKin
Upgrades
On Monday, 198 companies reached new 52-week lows.
On Friday, 153 companies set new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
On Monday, 147 stocks hit new 52-week lows.